Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Salutsantjoan     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com




Thursday, October 17, 2019

Hepatorenal syndrome

emDocs - October 14, 2019 - By Margus C and Beck-Esmay J 
Edited by: Koyfman A; Montrief T and Brit Long B)

"Pearls & Pitfalls

  • HRSis a high mortality complication of cirrhosis (1-7 month prognosis).
  • HRS likely develops when portal hypertension leads to release of excess vasodilators, thereby triggering a compensatory restriction to kidney perfusion and function.
  • HRS should be considered in all patients with cirrhosis + ascites + AKI refractory to volume resuscitation.
  • HRS is a diagnosis of exclusion, after diuretics and nephrotoxic agents have been stopped and shock and intrinsic renal pathology ruled out.
  • HRS evaluation is aided by ultrasound: to assess volume status, rule out obstructive nephropathy, and assist with paracentesis so as to exclude another big complication of cirrhosis, spontaneous bacterial peritonitis.
  • HRS is a cirrhotic AKI that can be diagnosed and treated with intravenous albumin supplementation at 1g/kg/day.
  • HRS vasoconstrictor therapy can be started in the ED with norepinephrine (0.5-3mg per hour IV infusion), but octreotide+ midodrine (octreotide 100-200mcg SQ every 8 hours; midodrine 7.5-12.5mg orally three times daily) is also an option, aiming for a MAP of 10 mmHg greater than the patient’s baseline.
  • HRS doesn’t exclude other complications of cirrhosis like SBP and abdominal compartment syndrome, and paracentesis should be considered with a low threshold to start empiric antibiotics (typically a third-generation cephalosporin)."